Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

rento's current beliefs and expectations, and should not be regarded as a representation by Sorrento that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Sorrento's businesses; the potential for approval and commercial success of Cynviloq; the scope and validity of patent protection for Sorrento's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; the potential that Sorrento may require substantial additional funding in order to obtain regulatory approval for and commercialize Sorrento's proprietary G-MAB® fully-human antibody library platform technologies or product candidates; and additional risks set forth in Sorrento's filings with the Securities and Exchange Commission. These forward-looking statements represent Sorrento Therapeutics' judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Sorrento undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.  


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 UBM Medica US today announced ... online community and information resource for neurologists and other ... their patients with neurological disorders . ... population, necessitates greater access to dedicated information for healthcare ... neurological conditions include: , 1 in 6 ...
(Date:7/23/2014)... , July 23, 2014 Research ... "Sensor Market in Consumer Healthcare by Application, Sensor ... to 2013 - 2020" report to their offering. ... There has been an increasing momentum for consumer healthcare ... and sophistication. The consumer healthcare will lessen the healthcare ...
(Date:7/23/2014)... DUBLIN , July 23, 2014 ... "Diagnostic Electrocardiograph (ECG) Market by Product, End-user & ... report to their offering. ... market is segmented into three major segments, namely, holter ... overall market was valued at $3,683 million in 2013 ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 2Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3
... Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a developer ... today that it will hold its 1st quarter 2011 investor ... James S. Kuo, M.D., M.B.A., Adeona,s Chief Executive Officer, will ... joined by special guest, Rhonda Voskuhl, M.D., Director, University of ...
... PRGO ; TASE) today announced that it has ... brought by Nycomed US Inc. by taking a license under ... can launch a generic version of Cutivate® lotion 0.05% on ... Cutivate® (fluticasone) lotion is indicated for the relief of ...
Cached Medicine Technology:Adeona to Host First Quarter 2011 Investor Conference Call 2Adeona to Host First Quarter 2011 Investor Conference Call 3Perrigo Announces Settlement of Cutivate Lotion Litigation 2
(Date:7/23/2014)... (PRWEB) July 23, 2014 The puffiness ... diminished using non-surgical techniques, according to a new guide ... eyes serum sold in the U.S. is now available ... . , The complimentary guide that is now published ... struggle with under eye puffiness. While surgical techniques are ...
(Date:7/23/2014)... has developed a simple, cheap and highly accurate ... which attacks immune deficient individuals such as cancer ... lateral-flow device (LFD), created by Professor Chris Thornton, ... diagnose disease caused by the fungus Aspergillus ... a leading cause of death in acute leukaemia ...
(Date:7/23/2014)... By Randy Dotinga ... (HealthDay News) -- A powerful drug combo may not ... New lab-based research on human cells suggests that one ... properly. However, this study,s findings aren,t definitive, and ... (brand name Kalydeco) and lumacaftor, according to the study,s ...
(Date:7/23/2014)... July 23, 2014 Home Care ... care for seniors, is proud to announce the next ... experts in a wide range of health and wellness-related ... worker and award-winning author Nancy Kriseman, and will cover ... to prevent burnout by becoming more self-aware. In particular, ...
(Date:7/23/2014)... China,s Northwest Agricultural and Forestry University in Shaanxi province, ... memorandum of agreement that lays the groundwork for establishing ... China. , The signing ceremony was held in the ... officials of the U.S. Department of Agriculture and China,s ... a landmark event for UC Davis and for our ...
Breaking Medicine News(10 mins):Health News:Puffy Eyes Serum Explored in Complimentary Guide Released at Consumer News Website 2Health News:New device detects deadly lung disease 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 3Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3
... pediatric combination for, immunization against diphtheria, tetanus, pertussis, polio and ... ... Pa. and LYON, France, June 23 Sanofi,Pasteur, the vaccines ... and Drug Administration (FDA) has licensed Pentacel(R),Diphtheria and Tetanus Toxoids ...
... decrease in health care and compensation benefits, ... economy, employers are managing to maintain a balance ... Survey released today by,the Society for Human Resource ... health care costs, combined with the state of ...
... NEW YORK, June 21 Many professionals,world-wide are calling ... force fluoridation on almost the whole state. SB 312 ... most Louisianans knowing,it was happening. The professionals are asking ... Citizens should have been part of this discussion,but they ...
... DELHI, India, June 20 The United States,has ... Save the Children to assist people affected by ... Shortages have emerged in recent months because ... in rapidly growing rat infestations in,crop-growing areas. With ...
... San Francisco,Medical Society (SFMS) announces the "David Perlman ... is presented each January at,the SFMS Annual Dinner ... television, radio and newspapers and magazines. The deadline ... award., A prestigious panel of SFMS journalists, ...
... life is greatly improved, too, , , FRIDAY, June 20 ... for many people with kidney disease, it can be ... blood as effectively as well-functioning kidneys do. , But, ... to change all that. , Nocturnal dialysis, not surprisingly, ...
Cached Medicine News:Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 5Health News:Despite Economic Downturn, Employee Benefits Remain Stable in 2008 2Health News:Professionals Ask Governor Jindal to Veto Unfair Fluoridation Bill 2Health News:SFMS David Perlman Award For Excellence in Medical/Health Reporting Recognizes Local Reporters 2Health News:Nocturnal Dialysis: A Better Way to Kidney Health 2Health News:Nocturnal Dialysis: A Better Way to Kidney Health 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: